UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000060895 |
|---|---|
| Receipt number | R000069667 |
| Scientific Title | Low doses of L-DOPA and CPZ therapy for obsessive compulsive disorder |
| Date of disclosure of the study information | 2026/03/12 |
| Last modified on | 2026/03/10 22:08:42 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Low doses of L-DOPA and CPZ therapy for obsessive compulsive disorder
Acronym
L-DOPA + CPZ therapy for OCD
Scientific Title
Low doses of L-DOPA and CPZ therapy for obsessive compulsive disorder
Scientific Title:Acronym
L-DOPA + CPZ therapy for OCD
Region
| Japan |
Condition
Condition
obsessive compulsive disorder
Classification by specialty
| Neurology | Psychiatry |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the efficacy and safety of chlorpromazine (CPZ) and LDOPA for the psychiatric symptoms of obsessive-compulsive disorder (OCD).
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
YALE-BROWN OBSESSIVE-COMPULSIVE SCALE
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
LDOPA 150 mg and chlorpromazine 15 mg were administered to patients with obsessive-compulsive disorder.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 120 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) Patients diagnosed with OCD according to DSM-5 and with a YBOCS score of 16 or higher.
2) Patients who have provided written consent to participate in the study.
3) Patients whose medications have not changed for at least three months.
Key exclusion criteria
Nothing in particular
Target sample size
9
Research contact person
Name of lead principal investigator
| 1st name | Shinichi |
| Middle name | |
| Last name | Matsumoto |
Organization
Osaka Neurological Institute
Division name
Department of Neurology
Zip code
561-0836
Address
Syounai, Toyonaka city 561-0836, Japan
TEL
06-6333-0080
dyt1mc@yahoo.co.jp
Public contact
Name of contact person
| 1st name | Shinichi |
| Middle name | |
| Last name | Matsumoto |
Organization
Osaka Neurological Institute
Division name
Department of Neurology
Zip code
561-0836
Address
Syounai, Toyonaka city 561-0836, Japan
TEL
06-6333-0080
Homepage URL
dyt1mc@yahoo.co.jp
Sponsor or person
Institute
Osaka Neurological Institute
Institute
Department
Personal name
Funding Source
Organization
Osaka Neurological Institute
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka Neurological Institute / IRB
Address
2-6-23 Shounai Takaramachi Toyonaka Osaka
Tel
06-6333-0080
dyt99mc@yahoo.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 03 | Month | 12 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
9
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2024 | Year | 05 | Month | 22 | Day |
Date of IRB
| 2024 | Year | 05 | Month | 22 | Day |
Anticipated trial start date
| 2024 | Year | 06 | Month | 23 | Day |
Last follow-up date
| 2027 | Year | 06 | Month | 22 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 03 | Month | 11 | Day |
Last modified on
| 2026 | Year | 03 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000069667
